For the year ending 2025-12-31, KLRS has $121,736K in assets. $42,922K in debts. $98,054K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 98,054 | |||
| Short-term marketable securities | 19,928 | |||
| Prepaid expenses and other current assets | 827 | |||
| Total current assets | 118,809 | |||
| Deferred transaction costs | 0 | |||
| Operating lease right-of-use assets | 1,475 | |||
| Restricted cash | 499 | |||
| Other non-current assets | 953 | |||
| Total assets | 121,736 | |||
| Accounts payable | 1,281 | |||
| Accrued expenses and other current liabilities (including 67 and 85 due to a related party) | 8,117 | |||
| Convertible promissory notes, net of discount of 1,298 (including 0 and 18,670 due to a related party) | 0 | |||
| Derivative liabilities (including 0 and 995 due to a related party) | 0 | |||
| Tranche liability (including 0 and 331 due to a related party) | 0 | |||
| Operating lease liabilities, current | 316 | |||
| Total current liabilities | 9,714 | |||
| Royalty obligation - related party | 32,076 | |||
| Operating lease liabilities, long-term | 1,132 | |||
| Total liabilities | 42,922 | |||
| Common stock, 0.0001 and 0.00001 par value as of december 31, 2025 and 2024, respectively 300,000,000 and 86,000,000 shares authorized as of december 31, 2025 and 2024, respectively 22,902,418 and 1,356,431 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 2 | |||
| Additional paid-in capital | 238,805 | |||
| Accumulated other comprehensive income | 6 | |||
| Accumulated deficit | -159,999 | |||
| Total stockholders' equity (deficit) | 78,814 | |||
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | 121,736 | |||
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)